Skip to main content

Prof. Dr. med. Markus Heim

Chefarzt Hepatologie

Forschungsgebiete: Behandlung der viralen chronischen Hepatitis, Interferon-Wirkung in der Leber, Entstehung des Leberkrebses


Seit 2019
Chefarzt Gastroenterologie und Hepatologie Clarunis Universitäres Bauchzentrum Basel

2012 – 2018
Chefarzt Gastroenterologie und Hepatologie Universitätsspital Basel

Facharzt für Hepatologie

Professor für Hepatologie 

2003– 2011
Leitender Arzt und Leiter Hepatologie Universitätsspital Basel

Ernennung zum Titularprofessor der Universität Basel

1999 – 2002 
Oberarzt Gastroenterologie und Hepatologie Universitätsspital Basel

Seit 1999
Forschungsgruppenleiter des Hepatologie Institut für Biomedizin Universität Basel

Facharzt für Gastroenterologie 

Habilitation in Innerer Medizin

1996 – 1997
Assistenzarzt für Gastroenterologie und Hepatologie Universitätsspital Basel

Facharzt für Innere Medizin 

1996 – 1997
Assistenzarzt für Gastroenterologie und Hepatologie Universitätsspital Freiburg 

1995 – 1996
Assistenzarzt Innere Medizin, Universitätsspital Basel 

1993 – 1995
Postdoctoral Fellow (J.E. Darnell) Rockefeller University New York

1991 – 1993
Assistenzarzt Innere Medizin Universitätsspital Basel

1988 – 1991
Postdoctoral Fellow (U.A.Meyer) Biozentrum Basel

Swiss Postgraduate Course in Experimental Medicine and Biology

1981 – 1987
Medizinstudium Universität Basel

  • Swiss Associaton for the Study of the Liver (SASL)
  • Swiss Society for Gastroenterology
  • European Association for the Study of the Liver (EASL)
  • Swiss Society for Internal Medicine (SGIM)
  • American Association for the Study of Liver Diseases (AASLD)
  • American Gastroenterology Association (AGA)
  • American Society for Microbiology (ASM) since 2001
  • American Society for Biochemistry and Molecular Biology (ASBMB)
  • International Society for Interferon and Cytokine Research (ISICR)
  • Ludwig-Heilmeyer-Gesellschaft
  1. Boldanova T, Fucile G, Vosshenrich J, Suslov A, Ercan C, Coto-Llerena M, Terracciano LM, Zech CJ, Boll DT, Wieland S, Heim MH: Supervised learning based on tumor imaging and biopsy transcriptomics predicts response of hepatocellular carcinoma to transarterial chemoembolization. Cell Rep Med. 2O21: 2: 1OO444.
  2. Chen Q, Coto-Llerena M, Suslov A, Teixeira RD, Fofana I, Nuciforo S, Hofmann M, Thimme R, Hensel N, Lohmann V, Ng CKY, Rosenberger G, Wieland S, Heim MH: Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses. Nat Commun. 2O21: 12: 4882.
  3. Coto-Llerena M, Lepore M, Spagnuolo J, Di Blasi D, Calabrese D, Suslov A, Bantug G, Duong FH, Terracciano LM, De Libero G, Heim MH: Interferon lambda 4 can directly activate human CD19(+) B cells and CD8(+) T cells. Life Sci Alliance. 2O21:4.
  4. Meier MA, Calabrese D, Suslov A, Terracciano LM, Heim MH, Wieland S: Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol. 2O21: 75: 84O-847.
  5. Suslov A, Meier MA, Ketterer S, Wang X, Wieland S, Heim MH: Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. J Hepatol. 2O21: 74: 794-8OO.
  6. Hess GF, Terracciano L, Heim M, Soysal SD, Kollmar O: Hepatectomy of a Hepatocellular Carcinoma after SIRT in a Cirrhotic Liver. Arch Surg Clin Case Rep 2020 3: 129
  7. Kinast V, Plociennikowska A, Anggakusuma, Bracht T, Todt D, Brown RJ, Boldanova T, Zhang Y, Brueggemann Y, Friesland M, Engelmann M, Vieyres G, Broering R, Vondran FWR, Heim MH, Sitek B, Bartenschlager R, Pietschmann T, Steinmann E. C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle. J Hepatol 2020.
  8. Di Blasi D, Boldanova T, Mori L, Terracciano L, Heim MH, De Libero G. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol 2020;9:195-218.
  9. Andreozzi M, Quintavalle C, Benz D, Quagliata L, Matter M, Calabrese D, Tosti N, Ruiz C, Trapani F, Tornillo L, Fusco A, Heim MH, Ng CKY, Pallante P, Terracciano LM, Piscuoglio S: Corrigendum to «HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models». Neoplasia. 2020 Jul; 22(7): 272–273
  10. Brenig R, Pop OT, Triantafyllou E, Geng A, Singanayagam A, Perez-Shibayama C, Besse L, Cupovic J, Kunzler P, Boldanova T, Brand S, Semela D, Duong FH, Weston CJ, Ludewig B, Heim MH, Wendon J, Antoniades CG, Bernsmeier C. Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis. Life Sci Alliance 2020;3.
  11. Wieland SF, Heim MH. The IFN-lambda Pony Express. Nat Immunol 2019.
  12. Tang F, Gao R, Jeevan-Raj B, Wyss CB, Kalathur RKR, Piscuoglio S, Ng CKY, Hindupur SK, Nuciforo S, Dazert E, Bock T, Song S, Buechel D, Morini MF, Hergovich A, Matthias P, Lim DS, Terracciano LM, Heim MH, Hall MN, Christofori G. LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function. Nat Commun 2019;10:5755.
  13. Flecken T, Meier MA, Skewes-Cox P, Barkan DT, Heim MH, Wieland SF, Holdorf MM. Mapping the heterogeneity of histone modifications on hepatitis B virus-DNA using liver needle biopsies obtained from chronically infected patients. J Virol 2019.
  14. Calabrese D, Roma G, Bergling S, Carbone W, Mele V, Nuciforo S, Fofana I, Campana B, Szkolnicka D, Hay DC, Tchorz J, Bouwmeester T, Wieland S, Heim MH. Liver biopsy derived induced pluripotent stem cells provide unlimited supply for the generation of hepatocyte-like cells. PLoS One 2019;14:e0221762.
  15. Blumer T, Fofana I, Matter MS, Wang X, Montazeri H, Calabrese D, Coto-Llerena M, Boldanova T, Nuciforo S, Kancherla V, Tornillo L, Piscuoglio S, Wieland S, Terracciano LM, Ng CKY, Heim MH. Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors. Hepatol Commun 2019;3:971-986.
  16. Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut 2018;67:953-962.
  17. Suslov A, Heim MH, Wieland S. New insights into HDV-induced innate immunity: MDA5 senses HDV replication. J Hepatol 2018;69:5-7.
  18. Suslov A, Boldanova T, Wang X, Wieland S, Heim MH. Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver. Gastroenterology 2018;154:1778-1790.
  19. Paradiso V, Garofoli A, Tosti N, Lanzafame M, Perrina V, Quagliata L, Matter MS, Wieland S, Heim MH, Piscuoglio S, Ng CKY, Terracciano LM. Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening. J Mol Diagn 2018;20:836-848.
  20. Nuciforo S, Fofana I, Matter MS, Blumer T, Calabrese D, Boldanova T, Piscuoglio S, Wieland S, Ringnalda F, Schwank G, Terracciano LM, Ng CKY, Heim MH. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Rep 2018;24:1363-1376.
  21. Ng CKY, Di Costanzo GG, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G, Perrina V, Quintavalle C, Boldanova T, Wieland S, Marino-Marsilia G, Lanzafame M, Quagliata L, Condorelli G, Matter MS, Tortora R, Heim MH, Terracciano LM, Piscuoglio S. Genetic profiling using plasma-derived cell-free DNA in therapy-naive hepatocellular carcinoma patients: a pilot study. Ann Oncol 2018;29:1286-1291.
  22. Hindupur SK, Colombi M, Fuhs SR, Matter MS, Guri Y, Adam K, Cornu M, Piscuoglio S, Ng CKY, Betz C, Liko D, Quagliata L, Moes S, Jenoe P, Terracciano LM, Heim MH, Hunter T, Hall MN. The protein histidine phosphatase LHPP is a tumour suppressor. Nature 2018;555:678-682.
  23. Goossens N, de Vito C, Mangia A, Clement S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Mullhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt L, Negro F, Group BS. Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. J Viral Hepat 2018;25:920-929.
  24. Campana B, Calabrese D, Matter MS, Terracciano LM, Wieland SF, Heim MH. In vivo analysis at the cellular level reveals similar steatosis induction in both hepatitis C virus genotype 1 and 3 infections. J Viral Hepat 2018;25:262-271.
  25. Broguiere N, Isenmann L, Hirt C, Ringel T, Placzek S, Cavalli E, Ringnalda F, Villiger L, Zullig R, Lehmann R, Rogler G, Heim MH, Schuler J, Zenobi-Wong M, Schwank G. Growth of Epithelial Organoids in a Defined Hydrogel. Adv Mater 2018;30:e1801621.
  26. Allgaier HP, Arnold C, Baumert TF, Becker G, Geissler M, Hafkemeyer P, Harder J, Heim MH, Huber R, Kern WV, Mohr L, Moradpour D, Offensperger S, Offensperger WB, Spangenberg HC, Thimme R, Walter E, von Weizsacker F. [From Molecuar to Natural Medicine]. Dtsch Med Wochenschr 2018;143:40-45.
  27. Rey S, Quintavalle C, Burmeister K, Calabrese D, Schlageter M, Quagliata L, Cathomas G, Diebold J, Molinolo A, Heim MH, Terracciano LM, Matter MS. Liver damage and senescence increases in patients developing hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:1480-1486.
  28. Quintavalle C, Hindupur SK, Quagliata L, Pallante P, Nigro C, Condorelli G, Andersen JB, Tagscherer KE, Roth W, Beguinot F, Heim MH, Ng CKY, Piscuoglio S, Matter MS. Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib. Cell Death Dis 2017;8:e3138.
  29. Meier MA, Suslov A, Ketterer S, Heim MH, Wieland SF. Hepatitis B virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway during chronic HBV infection. J Viral Hepat 2017;24:662-671.
  30. Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, Jenoe P, Heim MH, Riezman I, Riezman H, Hall MN. mTORC2 Promotes Tumorigenesis via Lipid Synthesis. Cancer Cell 2017;32:807-823 e812.
  31. Gauthiez E, Habfast-Robertson I, Rueger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Heim MH, Malinverni R, Moradpour D, Mullhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud PY, Swiss Hepatitis CCS. A systematic review and meta-analysis of HCV clearance. Liver Int 2017;37:1431-1445.
  32. Boldanova T, Suslov A, Heim MH, Necsulea A. Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liver. EMBO Mol Med 2017;9:816-834.
  33. Blumer T, Coto-Llerena M, Duong FHT, Heim MH. SOCS1 is an inducible negative regulator of interferon lambda (IFN-lambda)-induced gene expression in vivo. J Biol Chem 2017;292:17928-17938.
  34. Ulveling D, Le Clerc S, Cobat A, Labib T, Noirel J, Laville V, Coulonges C, Carpentier W, Nalpas B, Heim MH, Poynard T, Cerny A, Pol S, Bochud PY, Dabis F, Theodorou I, Levy Y, Salmon D, Abel L, Dominguez S, Zagury JF, Group HACCS, Swiss Hepatitis CCSG, French AHCEPGSG. A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2016;64:1462-1472.
  35. Themanns M, Mueller KM, Kessler SM, Golob-Schwarzl N, Mohr T, Kaltenecker D, Bourgeais J, Paier-Pourani J, Friedbichler K, Schneller D, Schlederer M, Zebedin-Brandl E, Terracciano LM, Han X, Kenner L, Wagner KU, Mikulits W, Kozlov AV, Heim MH, Gouilleux F, Haybaeck J, Moriggl R. Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice. Sci Rep 2016;6:34719.
  36. Planas-Paz L, Orsini V, Boulter L, Calabrese D, Pikiolek M, Nigsch F, Xie Y, Roma G, Donovan A, Marti P, Beckmann N, Dill MT, Carbone W, Bergling S, Isken A, Mueller M, Kinzel B, Yang Y, Mao X, Nicholson TB, Zamponi R, Capodieci P, Valdez R, Rivera D, Loew A, Ukomadu C, Terracciano LM, Bouwmeester T, Cong F, Heim MH, Forbes SJ, Ruffner H, Tchorz JS. Corrigendum: The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size. Nat Cell Biol 2016;18:1260.
  37. Planas-Paz L, Orsini V, Boulter L, Calabrese D, Pikiolek M, Nigsch F, Xie Y, Roma G, Donovan A, Marti P, Beckmann N, Dill MT, Carbone W, Bergling S, Isken A, Mueller M, Kinzel B, Yang Y, Mao X, Nicholson TB, Zamponi R, Capodieci P, Valdez R, Rivera D, Loew A, Ukomadu C, Terracciano LM, Bouwmeester T, Cong F, Heim MH, Forbes SJ, Ruffner H, Tchorz JS. The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size. Nat Cell Biol 2016;18:467-479.
  38. Mobin MB, Gerstberger S, Teupser D, Campana B, Charisse K, Heim MH, Manoharan M, Tuschl T, Stoffel M. The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation. Nat Commun 2016;7:12848.
  39. Makowska Z, Boldanova T, Adametz D, Quagliata L, Vogt JE, Dill MT, Matter MS, Roth V, Terracciano L, Heim MH. Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-based molecular classifications of hepatocellular carcinoma. J Pathol Clin Res 2016;2:80-92.
  40. Heim MH, Bochud PY, George J. Host - hepatitis C viral interactions: The role of genetics. J Hepatol 2016;65:S22-S32.
  41. Dazert E, Colombi M, Boldanova T, Moes S, Adametz D, Quagliata L, Roth V, Terracciano L, Heim MH, Jenoe P, Hall MN. Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. Proc Natl Acad Sci U S A 2016;113:1381-1386.
  42. Bernsmeier C, Dill MT, Provenzano A, Makowska Z, Krol I, Muscogiuri G, Semela D, Tornillo L, Marra F, Heim MH, Duong FH. Hepatic Notch1 deletion predisposes to diabetes and steatosis via glucose-6-phosphatase and perilipin-5 upregulation. Lab Invest 2016;96:972-980.
  43. Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB. Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis. J Virol 2016;90:6387-6400.
  44. Andreozzi M, Quintavalle C, Benz D, Quagliata L, Matter M, Calabrese D, Tosti N, Ruiz C, Trapani F, Tornillo L, Fusco A, Heim MH, Ng CK, Pallante P, Terracciano LM, Piscuoglio S. HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models. Neoplasia 2016;18:724-731.
  45. Terczynska-Dyla E, Bibert S, Duong FH, Krol I, Jorgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Malinverni R, Mangia A, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N, Swiss Hepatitis CCSG, Heim MH, Bochud PY, Hartmann R. Corrigendum: reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun 2015;6:7280.
  46. Rueger S, Bochud PY, Dufour JF, Mullhaupt B, Semela D, Heim MH, Moradpour D, Cerny A, Malinverni R, Booth DR, Suppiah V, George J, Argiro L, Halfon P, Bourliere M, Talal AH, Jacobson IM, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Negro F. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut 2015;64:1605-1615.
  47. Rothweiler S, Dill MT, Terracciano L, Makowska Z, Quagliata L, Hlushchuk R, Djonov V, Heim MH, Semela D. Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model. Lab Invest 2015;95:351-362.
  48. Pfaender S, Cavalleri JM, Walter S, Doerrbecker J, Campana B, Brown RJ, Burbelo PD, Postel A, Hahn K, Anggakusuma, Riebesehl N, Baumgartner W, Becher P, Heim MH, Pietschmann T, Feige K, Steinmann E. Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses. Hepatology 2015;61:447-459.
  49. Marti P, Stein C, Blumer T, Abraham Y, Dill MT, Pikiolek M, Orsini V, Jurisic G, Megel P, Makowska Z, Agarinis C, Tornillo L, Bouwmeester T, Ruffner H, Bauer A, Parker CN, Schmelzle T, Terracciano LM, Heim MH, Tchorz JS. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology 2015;62:1497-1510.
  50. Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lutgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 2015;33:549-554.
  51. Jansen L, de Niet A, Makowska Z, Dill MT, van Dort KA, Terpstra V, Bart Takkenberg R, Janssen HL, Heim MH, Kootstra NA, Reesink HW. An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B. Liver Int 2015;35:1824-1832.
  52. Frey RS, Boldanova T, Heim M. Ultrasound surveillance for hepatocellular carcinoma: real-life performance in a hepatology outpatient clinic. Swiss Med Wkly 2015;145:w14200.
  53. Bernsmeier C, Weisskopf DM, Pflueger MO, Mosimann J, Campana B, Terracciano L, Beglinger C, Heim MH, Cajochen C. Sleep Disruption and Daytime Sleepiness Correlating with Disease Severity and Insulin Resistance in Non-Alcoholic Fatty Liver Disease: A Comparison with Healthy Controls. PLoS One 2015;10:e0143293.
  54. Anggakusuma, Romero-Brey I, Berger C, Colpitts CC, Boldanova T, Engelmann M, Todt D, Perin PM, Behrendt P, Vondran FW, Xu S, Goffinet C, Schang LM, Heim MH, Bartenschlager R, Pietschmann T, Steinmann E. Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology 2015;62:702-714.
  55. Wieland S, Makowska Z, Campana B, Calabrese D, Dill MT, Chung J, Chisari FV, Heim MH. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 2014;59:2121-2130.
  56. Thimme R, Heim M, Baumert TF, Nassal M, Moradpour D. [Hepatitis B and C: From molecular virology to new antiviral therapies (part 1)]. Dtsch Med Wochenschr 2014;139:655-659.
  57. Thimme R, Heim M, Baumert TF, Nassal M, Moradpour D. [Hepatitis B and C: from molecular virology to new antiviral therapies (part 2)]. Dtsch Med Wochenschr 2014;139:778-782.
  58. Terczynska-Dyla E, Bibert S, Duong FH, Krol I, Jorgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Malinverni R, Mangia A, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N, Swiss Hepatitis CCSG, Heim MH, Bochud PY, Hartmann R. Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun 2014;5:5699.
  59. Rothweiler S, Terracciano L, Tornillo L, Dill MT, Heim MH, Semela D. Downregulation of the endothelial genes Notch1 and ephrinB2 in patients with nodular regenerative hyperplasia. Liver Int 2014;34:594-603.
  60. Rothweiler S, Heim MH, Semela D. Nodular regenerative hyperplasia in a patient with generalized essential telangiectasia: endotheliopathy as a causal factor. Hepatology 2014;59:2419-2421.
  61. Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z, Boldanova T, Andersen JB, Hammerle M, Tornillo L, Heim MH, Diederichs S, Cillo C, Terracciano LM. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology 2014;59:911-923.
  62. Quagliata L, Andreozzi M, Kovac M, Tornillo L, Makowska Z, Moretti F, Heim MH, Heinimann K, Piscuoglio S, Terracciano LM. SH2D4A is frequently downregulated in hepatocellular carcinoma and cirrhotic nodules. Eur J Cancer 2014;50:731-738.
  63. Morikawa K, Gouttenoire J, Hernandez C, Dao Thi VL, Tran HT, Lange CM, Dill MT, Heim MH, Donze O, Penin F, Quadroni M, Moradpour D. Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease. Hepatology 2014;59:423-433.
  64. Morard I, Clement S, Calmy A, Mangia A, Cerny A, De Gottardi A, Gorgievski M, Heim M, Malinverni R, Moradpour D, Mullhaupt B, Semela D, Pascarella S, Bochud PY, Negro F, Swiss Hepatitis CCSG. Clinical significance of the CCR5delta32 allele in hepatitis C. PLoS One 2014;9:e106424.
  65. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Huser N, Durantel D, Liang TJ, Munk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-1228.
  66. Liakoni E, Ratz Bravo AE, Terracciano L, Heim M, Krahenbuhl S. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med 2014;174:1683-1686.
  67. Lange CM, Gouttenoire J, Duong FH, Morikawa K, Heim MH, Moradpour D. Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to IFN-alpha. J Immunol 2014;192:6037-6044.
  68. Hoggart CJ, Venturini G, Mangino M, Gomez F, Ascari G, Zhao JH, Teumer A, Winkler TW, Tsernikova N, Luan J, Mihailov E, Ehret GB, Zhang W, Lamparter D, Esko T, Mace A, Rueger S, Bochud PY, Barcella M, Dauvilliers Y, Benyamin B, Evans DM, Hayward C, Lopez MF, Franke L, Russo A, Heid IM, Salvi E, Vendantam S, Arking DE, Boerwinkle E, Chambers JC, Fiorito G, Grallert H, Guarrera S, Homuth G, Huffman JE, Porteous D, Generation Scotland C, LifeLines Cohort s, Consortium G, Moradpour D, Iranzo A, Hebebrand J, Kemp JP, Lammers GJ, Aubert V, Heim MH, Martin NG, Montgomery GW, Peraita-Adrados R, Santamaria J, Negro F, Schmidt CO, Scott RA, Spector TD, Strauch K, Volzke H, Wareham NJ, Yuan W, Bell JT, Chakravarti A, Kooner JS, Peters A, Matullo G, Wallaschofski H, Whitfield JB, Paccaud F, Vollenweider P, Bergmann S, Beckmann JS, Tafti M, Hastie ND, Cusi D, Bochud M, Frayling TM, Metspalu A, Jarvelin MR, Scherag A, Smith GD, Borecki IB, Rousson V, Hirschhorn JN, Rivolta C, Loos RJ, Kutalik Z. Novel approach identifies SNPs in SLC2A10 and KCNK9 with evidence for parent-of-origin effect on body mass index. PLoS Genet 2014;10:e1004508.
  69. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol 2014;61:S14-25.
  70. Haid S, Grethe C, Dill MT, Heim M, Kaderali L, Pietschmann T. Isolate-dependent use of claudins for cell entry by hepatitis C virus. Hepatology 2014;59:24-34.
  71. Frentzen A, Anggakusuma, Gurlevik E, Hueging K, Knocke S, Ginkel C, Brown RJ, Heim M, Dill MT, Kroger A, Kalinke U, Kaderali L, Kuehnel F, Pietschmann T. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Hepatology 2014;59:78-88.
  72. Frei P, Leucht AK, Held U, Kofmehl R, Manser CN, Schmitt J, Mertens J, Rau M, Baur K, Gerlach T, Negro F, Heim M, Moradpour D, Cerny A, Dufour JF, Mullhaupt B, Geier A, Swiss Hepatitis CCSG. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-alpha and ribavirin in chronic hepatitis C virus patients. Liver Int 2014;34:551-557.
  73. Duong FH, Trincucci G, Boldanova T, Calabrese D, Campana B, Krol I, Durand SC, Heydmann L, Zeisel MB, Baumert TF, Heim MH. IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies. J Exp Med 2014;211:857-868.
  74. Duong FH, Dill MT, Matter MS, Makowska Z, Calabrese D, Dietsche T, Ketterer S, Terracciano L, Heim MH. Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53. Carcinogenesis 2014;35:114-122.
  75. Dill MT, Makowska Z, Trincucci G, Gruber AJ, Vogt JE, Filipowicz M, Calabrese D, Krol I, Lau DT, Terracciano L, van Nimwegen E, Roth V, Heim MH. Pegylated IFN-alpha regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest 2014;124:1568-1581.
  76. Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, Heim MH, Beglinger C. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One 2014;9:e87488.
  77. Bernsmeier C, Calabrese D, Heim MH, Duong HT. Hepatitis C virus dysregulates glucose homeostasis by a dual mechanism involving induction of PGC1alpha and dephosphorylation of FoxO1. J Viral Hepat 2014;21:9-18.
  78. Balmer ML, Slack E, de Gottardi A, Lawson MA, Hapfelmeier S, Miele L, Grieco A, Van Vlierberghe H, Fahrner R, Patuto N, Bernsmeier C, Ronchi F, Wyss M, Stroka D, Dickgreber N, Heim MH, McCoy KD, Macpherson AJ. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med 2014;6:237ra266.
  79. Zona L, Lupberger J, Sidahmed-Adrar N, Thumann C, Harris HJ, Barnes A, Florentin J, Tawar RG, Xiao F, Turek M, Durand SC, Duong FH, Heim MH, Cosset FL, Hirsch I, Samuel D, Brino L, Zeisel MB, Le Naour F, McKeating JA, Baumert TF. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 2013;13:302-313.
  80. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Bocher WO, Mensa FJ. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther 2013;18:1015-1019.
  81. Shanker V, Trincucci G, Heim HM, Duong HT. Protein phosphatase 2A impairs IFNalpha-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation. J Viral Hepat 2013;20:612-621.
  82. Makowska Z, Blumer T, Duong FH, La Monica N, Kandimalla ER, Heim MH. Sequential induction of type I and II interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist. J Hepatol 2013;58:743-749.
  83. Lupberger J, Duong FH, Fofana I, Zona L, Xiao F, Thumann C, Durand SC, Pessaux P, Zeisel MB, Heim MH, Baumert TF. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology 2013;58:1225-1235.
  84. Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Mullhaupt B, Negro F, Semela D, Kutalik Z, Muller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY, Hiroshima Liver Study G, Swiss Hepatitis CCSG. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS One 2013;8:e64053.
  85. Lange CM, Bibert S, Dufour JF, Cellerai C, Cerny A, Heim MH, Kaiser L, Malinverni R, Mullhaupt B, Negro F, Semela D, Moradpour D, Kutalik Z, Bochud PY, Swiss Hepatitis CCSG. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. J Hepatol 2013;59:504-509.
  86. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol 2013;13:535-542.
  87. Heim MH. Innate immunity and HCV. J Hepatol 2013;58:564-574.
  88. Heim M. Reply to miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection. Nat Rev Immunol 2013;13:902.
  89. Dill MT, Tornillo L, Fritzius T, Terracciano L, Semela D, Bettler B, Heim MH, Tchorz JS. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology 2013;57:1607-1619.
  90. Swiss Association for the Study of the L. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. Swiss Med Wkly 2012;142:w13516.
  91. Stickel F, Helbling B, Heim M, Geier A, Hirschi C, Terziroli B, Wehr K, De Gottardi A, Negro F, Gerlach T. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. J Viral Hepat 2012;19:77-87.
  92. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Mullhaupt B, Semela D, Dufour JF, Heim MH, Moradpour D, Cerny A, Malinverni R, Hirsch H, Martinetti G, Suppiah V, Stewart G, Booth DR, George J, Casanova JL, Brechot C, Rice CM, Talal AH, Jacobson IM, Bourliere M, Theodorou I, Poynard T, Negro F, Pol S, Bochud PY, Abel L, Swiss Hepatitis C Cohort Study Group IHCGC, French AHCEPGSG. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 2012;143:1244-1252 e1212.
  93. Makowska Z, Heim MH. Interferon signaling in the liver during hepatitis C virus infection. Cytokine 2012;59:460-466.
  94. Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme R, Arasteh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M, Kukolj G, Bocher W, Steffgen J. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 2012;57:39-46.
  95. Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, Dufour JF, Gerlach TJ, Heim MH, Malinverni R, Mullhaupt B, Negro F, Moradpour D, Bochud PY, Swiss Hepatitis CCSG. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology 2012;55:1038-1047.
  96. Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhoop K, Bojunga J, Sarrazin C, Zeuzem S, Muller T, Berg T, Bochud PY, Moradpour D, Swiss Hepatitis CCSG. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One 2012;7:e40159.
  97. Kuske L, Mensen A, Mullhaupt B, Negro F, Semela D, Moradpour D, Male PJ, Heim MH, Malinverni R, Cerny A, Dufour JF, Swiss Hepatitis CCS. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. Swiss Med Wkly 2012;142:w13651.
  98. Heim MH. Interferons and hepatitis C virus. Swiss Med Wkly 2012;142:w13586.
  99. Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, Terracciano L, Heim MH, Ruegg MA, Hall MN. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 2012;15:725-738.
  100. Garaigorta U, Heim MH, Boyd B, Wieland S, Chisari FV. Hepatitis C virus (HCV) induces formation of stress granules whose proteins regulate HCV RNA replication and virus assembly and egress. J Virol 2012;86:11043-11056.
  101. Friedbichler K, Themanns M, Mueller KM, Schlederer M, Kornfeld JW, Terracciano LM, Kozlov AV, Haindl S, Kenner L, Kolbe T, Mueller M, Snibson KJ, Heim MH, Moriggl R. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology 2012;55:941-952.
  102. Dill MT, Rothweiler S, Djonov V, Hlushchuk R, Tornillo L, Terracciano L, Meili-Butz S, Radtke F, Heim MH, Semela D. Disruption of Notch1 induces vascular remodeling, intussusceptive angiogenesis, and angiosarcomas in livers of mice. Gastroenterology 2012;142:967-977 e962.
  103. Dill MT, Makowska Z, Duong FHT, Merkofer F, Filipowicz M, Baumert TF, Tornillo L, Terracciano L, Heim MH. Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 2012;143:777-786 e776.
  104. Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, Goossens N, Kuske L, Mullhaupt B, Gerlach T, Heim MH, Moradpour D, Cerny A, Malinverni R, Regenass S, Dollenmaier G, Hirsch H, Martinetti G, Gorgiewski M, Bourliere M, Poynard T, Theodorou I, Abel L, Pol S, Dufour JF, Negro F, Swiss Hepatitis CCSG, Group AHEGS. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012;55:384-394.
  105. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Kukolj G, Nehmiz G, Haefner C, Boecher WO. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011;141:2047-2055; quiz e2014.
  106. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, Heim MH, Stoffel M. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011;474:649-653.
  107. Semela D, Heim M. [Hepatocellular carcinoma]. Ther Umsch 2011;68:213-217.
  108. Mullhaupt B, Durand F, Roskams T, Dutkowski P, Heim M. Is tumor biopsy necessary? Liver Transpl 2011;17 Suppl 2:S14-25.
  109. Mueller KM, Kornfeld JW, Friedbichler K, Blaas L, Egger G, Esterbauer H, Hasselblatt P, Schlederer M, Haindl S, Wagner KU, Engblom D, Haemmerle G, Kratky D, Sexl V, Kenner L, Kozlov AV, Terracciano L, Zechner R, Schuetz G, Casanova E, Pospisilik JA, Heim MH, Moriggl R. Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology 2011;54:1398-1409.
  110. Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH. Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo. Hepatology 2011;53:1154-1163.
  111. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, Roth V, Heim MH. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011;140:1021-1031.
  112. Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, Cerny A, Malinverni R, Kaddai V, Bochud M, Negro F, Bochud PY. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol 2011;55:529-535.
  113. Sgier C, Mullhaupt B, Gerlach T, Moradpour D, Negro F, Male PJ, Heim MH, Malinverni R, Cerny A, Dufour JF. Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. J Viral Hepat 2010;17:845-850.
  114. Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, Neumann U, Schmidt HH, Spengler U, Wirth S, Kessler HH, Peck-Radosavljevic M, Ferenci P, Vogel W, Moradpour D, Heim M, Cornberg M, Protzer U, Manns MP, Fleig WE, Dollinger MM, Zeuzem S. [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol 2010;48:289-351.
  115. Ripoli M, D'Aprile A, Quarato G, Sarasin-Filipowicz M, Gouttenoire J, Scrima R, Cela O, Boffoli D, Heim MH, Moradpour D, Capitanio N, Piccoli C. Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1 alpha-mediated glycolytic adaptation. J Virol 2010;84:647-660.
  116. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, Swiss Hepatitis CCS, Swiss HIVCS. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-1345, 1345 e1331-1337.
  117. Overbeck K, Dufour JF, Mullhaupt B, Helbling B, Borovicka J, Malinverni R, Heim M, Moradpur D, Cerny A, Rickenbach M, Negro F. Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland. Swiss Med Wkly 2010;140:146-152.
  118. Kim MJ, Heim M, Mayr M. Effect of corticosteroids during ongoing drug exposure in pantoprazole-induced interstitial nephritis. Nephrol Dial Transplant 2010;25:1716-1719.
  119. Heim MH. Interferon Signaling. In: J.-F. Dufour P-AC, editor. Signaling Pathways in Liver Diseases. Berlin Heidelberg: Springer-Verlag; 2010.
  120. Gonvers JJ, Heim MH, Cavassini M, Mullhaupt B, Genne D, Bernasconi E, Borovicka J, Cerny A, Chave JP, Chuard C, Dufour F, Dutoit V, Malinverni R, Monnat M, Negro F, Troilliet N, Oneta C. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. Swiss Med Wkly 2010;140:w13055.
  121. Filipowicz M, Bernsmeier C, Terracciano L, Duong FH, Heim MH. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One 2010;5:e15492.
  122. Duong FH, Christen V, Lin S, Heim MH. Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair. Hepatology 2010;51:741-751.
  123. Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 2010;15:1198-1204.
  124. Bellecave P, Sarasin-Filipowicz M, Donze O, Kennel A, Gouttenoire J, Meylan E, Terracciano L, Tschopp J, Sarrazin C, Berg T, Moradpour D, Heim MH. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 2010;51:1127-1136.
  125. Bareiss D, Semela D, Heim M, Terracciano L, Hunziker S. [44 year old gardener with lower back pain, myalgia and fever]. Praxis (Bern 1994) 2010;99:127-132.
  126. Tchorz JS, Kinter J, Muller M, Tornillo L, Heim MH, Bettler B. Notch2 signaling promotes biliary epithelial cell fate specification and tubulogenesis during bile duct development in mice. Hepatology 2009;50:871-879.
  127. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, Hilton DJ, Zhang DE, Heim MH. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009;29:4841-4851.
  128. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009;15:31-33.
  129. Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M, Swiss Hepatitis CCSG. Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. J Viral Hepat 2009;16:644-649.
  130. Heim MH. HCV innate immune responses. Viruses 2009;1:1073-1088.
  131. Dinges S, Morard I, Heim M, Dufour JF, Mullhaupt B, Giostra E, Clavien PA, Mentha G, Negro F, Swiss Association for the Study of the L. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. Transpl Infect Dis 2009;11:33-39.
  132. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F, Swiss Hepatitis CCSG. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655-666.
  133. Bernsmeier C, Heim MH. Insulin resistance in chronic hepatitis C: mechanisms and clinical relevance. Swiss Med Wkly 2009;139:678-684.
  134. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008;105:7034-7039.
  135. Khanlari B, Bodmer M, Terracciano L, Heim MH, Fluckiger U, Weisser M. Hepatitis with fibrin-ring granulomas. Infection 2008;36:381-383.
  136. Helbling B, Overbeck K, Gonvers JJ, Malinverni R, Dufour JF, Borovicka J, Heim M, Cerny A, Negro F, Bucher S, Rickenbach M, Renner EL, Mullhaupt B, Swiss Hepatitis CCS. Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut 2008;57:1597-1603.
  137. Giovanoli O, Heim M, Terracciano L, Bongartz G, Ledermann HP. MRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patients. AJR Am J Roentgenol 2008;190:W290-293.
  138. Ciuffreda D, Comte D, Cavassini M, Giostra E, Buhler L, Perruchoud M, Heim MH, Battegay M, Genne D, Mulhaupt B, Malinverni R, Oneta C, Bernasconi E, Monnat M, Cerny A, Chuard C, Borovicka J, Mentha G, Pascual M, Gonvers JJ, Pantaleo G, Dutoit V. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol 2008;38:2665-2677.
  139. Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, Heim MH. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol 2008;49:429-440.
  140. Heim MH, Jacob L, Beglinger C. The angiotensin II receptor antagonist candesartan is not effective in reducing portal hypertension in patients with cirrhosis. Digestion 2007;75:122-123.
  141. Gilgen-Anner Y, Heim M, Ledermann HP, Bircher AJ. Iodide mumps after contrast media imaging: a rare adverse effect to iodine. Ann Allergy Asthma Immunol 2007;99:93-98.
  142. Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 2007;46:558-565.
  143. Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol 2007;81:159-165.
  144. Duong FH, Christen V, Filipowicz M, Heim MH. S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro. Hepatology 2006;43:796-806.
  145. Schnyder B, Schnyder-Candrian S, Pansky A, Schmitz ML, Heim M, Ryffel B, Moser R. IL-17 reduces TNF-induced Rantes and VCAM-1 expression. Cytokine 2005;31:191-202.
  146. Sadallah S, Heim M, Hess C, Klimkait T, Battegay M, Schifferli JA. Contrary to HIV, hepatitis C virus is not associated with erythrocytes in vivo. J Hepatol 2005;42:150-152.
  147. Moradpour D, Heim MH, Blum HE. Mechanisms of interferon resistance. In: Thomas HC, Lemon SM, Zuckerman AJ, editors. Viral Hepatitis, Third Edition ed. Malden, MA; Oxford, UK; Carlton, Victoria, Australia: Blackwell Publishing; 2005. p. 815-823.
  148. Heim MH. RIG-I: an essential regulator of virus-induced interferon production. J Hepatol 2005;42:431-433.
  149. Duong FH, Christen V, Berke JM, Penna SH, Moradpour D, Heim MH. Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1. J Virol 2005;79:15342-15350.
  150. Croquelois A, Blindenbacher A, Terracciano L, Wang X, Langer I, Radtke F, Heim MH. Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology 2005;41:487-496.
  151. Heim MH. [Autoimmune hepatitis]. Ther Umsch 2004;61:499-504.
  152. Duong FH, Filipowicz M, Tripodi M, La Monica N, Heim MH. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004;126:263-277.
  153. Blanchard C, Durual S, Estienne M, Bouzakri K, Heim MH, Blin N, Cuber JC. IL-4 and IL-13 up-regulate intestinal trefoil factor expression: requirement for STAT6 and de novo protein synthesis. J Immunol 2004;172:3775-3783.
  154. Wiederkehr-Adam M, Ernst P, Muller K, Bieck E, Gombert FO, Ottl J, Graff P, Grossmuller F, Heim MH. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. J Biol Chem 2003;278:16117-16128.
  155. Tietz A, Heim MH, Eriksson U, Marsch S, Terracciano L, Krahenbuhl S. Fulminant liver failure associated with clarithromycin. Ann Pharmacother 2003;37:57-60.
  156. Moradpour D, Heim MH, Cerny A, Rice CM, Blum HE. Cell lines that allow regulated expression of HCV proteins: principles and applications. In: Schinazi RF, Sommadossi J-P, Rice CM, editors. Frontiers in Viral Hepatitis. Amsterdam: Elsevier B.V.; 2003. p. 175-186.
  157. Heim MH. Reply. Hepatology 2003;38:1591.
  158. Heim MH. The STAT protein family. In: Sehgal PB, Levy DE, Hirano T, editors. Signal Transducers and Activators of Transcription (STATs) Activation and Biology. Dordrecht/Boston/London: Kluwer Academic Publishers; 2003. p. 11-26.
  159. Heim MH. A new survival trick of hepatitis C virus: blocking the activation of interferon regulatory factor-3. Hepatology 2003;38:1582-1584.
  160. Blindenbacher A, Wang X, Langer I, Savino R, Terracciano L, Heim MH. Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology 2003;38:674-682.
  161. Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M, La Monica N, Heim MH. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003;124:1465-1475.
  162. Wiesner W, Kocher T, Heim M, Bongartz G. CT findings in eosinophilic enterocolitis with predominantly serosal and muscular bowel wall infiltration. JBR-BTR 2002;85:4-6.
  163. Staedele H, Wiesner W, Heim M, Bongartz G. Potentially misleading CT findings in fatty liver cirrhosis. Eur Radiol 2002;12:946-947.
  164. Schnyder B, Schnyder-Candrian S, Panski A, Bommel H, Heim M, Duschl A, Moser R. Phytochemical inhibition of interleukin-4-activated Stat6 and expression of VCAM-1. Biochem Biophys Res Commun 2002;292:841-847.
  165. Moradpour D, Frese M, Heim MH, Haller O, Bartenschlager R, Blum HE. Cytokines and hepatitis C virus replication. In: Gressner AM, Heinrich PC, Matern S, editors. Cytokines in Liver Injury and Repair. Dordrecht, Boston, London: Kluwer Academic Publishers; 2002. p. 105-120.
  166. Moradpour D, Wolk B, Cerny A, Heim MH, Blum HE. Hepatitis C: a concise review. Minerva Med 2001;92:329-339.
  167. Moradpour D, Cerny A, Heim MH, Blum HE. Hepatitis C: an update. Swiss Med Wkly 2001;131:291-298.
  168. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, Heim MH. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000;85:720-725.
  169. Moradpour D, Heim MH, Blum HE. Interferons and viral replication in the liver. In: Andus T, Rogler G, Schlottmann K, Frick E, Adler G, Zeitz M, et al., editors. Cytokines and Cell Homeostasis in the Gastrointestinal Tract. Dordrecht/Boston/London: Kluwer Academic Publisher; 2000. p. 192-205.
  170. Heim MH. Intracellular signalling and antiviral effects of interferons. Dig Liver Dis 2000;32:257-263.
  171. Donda A, Mori L, Shamshiev A, Carena I, Mottet C, Heim MH, Beglinger C, Grunert F, Rochlitz C, Terracciano L, Jantscheff P, De Libero G. Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response. Eur J Immunol 2000;30:2593-2603.
  172. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999;73:8469-8475.
  173. Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res 1999;19:75-120.
  174. Steiger JU, Nickerson PW, Hermle M, Thiel G, Heim MH. Interferon-gamma receptor signaling is not required in the effector phase of the alloimmune response. Transplantation 1998;65:1649-1652.
  175. Pansky A, Hildebrand P, Heim MH, Eberhard M, Kissel T, Beglinger C. Growth effects of alpha-interferon but not of bombesin or angiotensin II are mediated by activation of STAT proteins. Eur J Clin Invest 1998;28:398-406.
  176. Heuss LT, Heim MH, Schultz U, Wissmann D, Offensperger WB, Staeheli P, Blum HE. Biological efficacy and signal transduction through STAT proteins of recombinant duck interferon in duck hepatitis B virus infection. J Gen Virol 1998;79 ( Pt 8):2007-2012.
  177. Heim MH. Intracellular signalling and biological effects of leptin. In: Häussinger D, Heinrich PC, editors. Signalling in the Liver. Dordrecht/Boston/London: Kluwer Academic Publishers; 1998. p. 89-97.
  178. Feng N, Lugli SM, Schnyder B, Gauchat JF, Graber P, Schlagenhauf E, Schnarr B, Wiederkehr-Adam M, Duschl A, Heim MH, Lutz RA, Moser R. The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: overexpression of the nonsignaling interleukin-13 receptor alpha2. Lab Invest 1998;78:591-602.
  179. Fasler-Kan E, Pansky A, Wiederkehr M, Battegay M, Heim MH. Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur J Biochem 1998;254:514-519.
  180. Pless M, Norga K, Carroll M, Heim MH, D'Andrea AD, Mathey-Prevot B. Receptors that induce erythroid differentiation of Ba/F3 cells: structural requirements and effect on STAT5 binding. Blood 1997;89:3175-3185.
  181. Lugli SM, Feng N, Heim MH, Adam M, Schnyder B, Etter H, Yamage M, Eugster HP, Lutz RA, Zurawski G, Moser R. Tumor necrosis factor alpha enhances the expression of the interleukin (IL)-4 receptor alpha-chain on endothelial cells increasing IL-4 or IL-13-induced Stat6 activation. J Biol Chem 1997;272:5487-5494.
  182. Heim MH, Gamboni G, Beglinger C, Gyr K. Specific activation of AP-1 but not Stat3 in regenerating liver in mice. Eur J Clin Invest 1997;27:948-955.
  183. Heim MH. The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus. Eur J Clin Invest 1996;26:1-12.
  184. Heim MH. [A case from practice (355). Acute myeloid leukemia. Small and large intestine diverticulosis with suspicion of a covered perforation with chronic abscess formation]. Praxis (Bern 1994) 1996;85:1009-1010.
  185. Heim M. [A case from practice (357)]. Praxis (Bern 1994) 1996;85:1185-1186.
  186. Ghilardi N, Ziegler S, Wiestner A, Stoffel R, Heim MH, Skoda RC. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci U S A 1996;93:6231-6235.
  187. Heim MH, Kerr IM, Stark GR, Darnell JE, Jr. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 1995;267:1347-1349.
  188. Meyer UA, Skoda RC, Zanger UM, Heim MH, Broly F. The genetic polymorphism of debrisoquine/sparteine metabolism - molecular mechanisms. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York.: Pergamon Press Inc.; 1992. p. 609-623.
  189. Meyer UA, Blum M, Grant D, Heim MH, Broly F, Hoffmann M, Probst M, Garcia-Agundez J. Acetylation pharmacogenetics. In: Jeffrey EH, editor. Human drug metabolism: From molecular biology to man. Boca Raton, Florida.: CRC Press Inc.; 1992.
  190. Heim MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992;14:49-58.
  191. Heim MH. Polymerase chain reaction and its potential as a pharmacokinetic tool. Clin Pharmacokinet 1992;23:321-327.
  192. Johansson I, Yue QY, Dahl ML, Heim M, Sawe J, Bertilsson L, Meyer UA, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991;40:553-556.
  193. Heim MH, Meyer UA. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6. Methods Enzymol 1991;206:173-183.
  194. Heim MH, Blum M, Beer M, Meyer UA. Acetylation of serotonin in the rabbit pineal gland: an N-acetyltransferase with properties distinct from NAT1 and NAT2 is responsible. J Neurochem 1991;57:1095-1099.
  195. Heim M, Meyer UA. Predicting debrisoquine phenotype. Lancet 1991;337:363.
  196. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-558.
  197. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A 1991;88:5237-5241.
  198. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990;265:17209-17214.
  199. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-532.
  200. Blum M, Heim M, Meyer UA. Nucleotide sequence of rabbit NAT1 encoding monomorphic arylamine N-acetyltransferase. Nucleic Acids Res 1990;18:5287.
  201. Blum M, Heim M, Meyer UA. Nucleotide sequence of rabbit NAT2 encoding polymorphic liver arylamine N-acetyltransferase (NAT). Nucleic Acids Res 1990;18:5295.
  202. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990;9:193-203.